Hemoglobinopathies Market

May 2021| MRS229A| Market Research Studies

Report Highlights

The report focused on the different test types of hemoglobinopathies. The report also focused on the different treatment involved for hemoglobinopathies. Furthermore, the scope of the report also covers the impact of COVID-19 and drivers and challenges for Hemoglobinopathies market. The report covers the market value for the historic year 2019, followed by the base year 2020, estimated year 2021 and forecast period from 2020 to 2026 for each indication, test type, treatment, end-user, and regional markets, and the estimated values are derived from the manufacturers’ total revenues.

The report also includes a discussion of the major players across each of the regional hemoglobinopathies markets; it explains the major market drivers of the global hemoglobinopathies industry, current trends within the industry, major applications, and the regional dynamics of the global hemoglobinopathies market.

The report concludes with a special focus on the vendor landscape, which includes detailed profiles of the major vendors in the global hemoglobinopathies market.

Report Includes

  • 41 tables and 49 figures
  • An up-to-date analysis of the Global Hemoglobinopathies Market.
  • Analyses of the global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026.
  • Estimation of market size and revenue forecast for Global Hemoglobinopathies Market, and corresponding market share analysis by indication, test type, treatment, end-user, and region.
  • Highlights of emerging technology trends, gaps and opportunities in the market estimating current and future demand for Hemoglobinopathies, identification of the companies that are best positioned to meet this demand.
  • In-depth information (facts and figures) concerning market drivers, restraints and other forces affecting the progress of this market.
  • Identification of promising new therapies, and products still in the development and testing stages, and their probability of successful commercial launch within the next five years
  • Impact of COVID-19 on the Hemoglobinopathies Market as compared to overall global economy.
  • Insight into the growth development strategies of major Hemoglobinopathies manufacturers and their key competitive landscape
  • Descriptive company profiles of the leading market participants, including Sangamo Therapeutics, Inc., Global Blood Therapeutics, Inc., Emmaus Life Sciences Inc., Pfizer, Inc., Novartis International AG, Danaher Corporation, and others.

Summary

The hemoglobinopathies are a cluster of disorders which are inherited from the family and in this disorder, there is an unusual production of the haemoglobin molecule. Sickle cell disease and thalassemia are some of the examples of such blood disorder which are caused by abnormality in the haemoglobin. This abnormality could further lead to damaging of the red blood cells.

Some of the drugs which are involved in treating different symptoms of hemoglobinopathies include analgesics, antibiotics, ACE inhibitors, and many others. Usually, stem cell therapy or blood transfusion is a common process which is followed for treating patients suffering from hemoglobinopathies disorders.

It has been observed that approximately 250 million people carry a potential hemoglobinopathy gene. Every year about 0.3 million children are born with a hemoglobinopathy disorder. The growth of hemoglobinopathies is developing in the low and middle-income countries.

The American Society of Hematology, has stated that approximately 95% of the children are born with thalassemia are mainly from low and middle-income countries. However, lacking clinical trials for curing sickle cell anaemia are expected to impede the market growth.

The Global Hemoglobinopathies Market was valued at $6.84 billion in 2020 and is expected to witness a steady growth at a CAGR of 7.26% during the forecast period.

  • Table 1 : Global Hemoglobinopathies Market, Through 2026
  • Table 2 : Global Hemoglobinopathies Market, by Indication, Through 2026
  • Table 3 : Global Hemoglobinopathies Market, by Test Type, Through 2026
  • Table 4 : Global Hemoglobinopathies Market, by Treatment, Through 2026
  • Table 5 : Global Hemoglobinopathies Market, by End-User, Through 2026
  • Table 6 : Global Hemoglobinopathies Market, by Region, Through 2026
  • Table 7 : North America Hemoglobinopathies Market, by Indication, Through 2026
  • Table 8 : North America Hemoglobinopathies Market, by Test Type, Through 2026
  • Table 9 : North America Hemoglobinopathies Market, by Treatment, Through 2026
  • Table 10 : North America Hemoglobinopathies Market, by End-User, Through 2026
  • Table 11 : North America Hemoglobinopathies Market, by Country, Through 2026
  • Table 12 : Europe Hemoglobinopathies Market, by Indication, Through 2026
  • Table 13 : Europe Hemoglobinopathies Market, by Test Type, Through 2026
  • Table 14 : Europe Hemoglobinopathies Market, by Treatment, Through 2026
  • Table 15 : Europe Hemoglobinopathies Market, by End-User, Through 2026
  • Table 16 : Europe Hemoglobinopathies Market, by Country, Through 2026
  • Table 17 : Asia-Pacific Hemoglobinopathies Market, by Indication, Through 2026
  • Table 18 : Asia-Pacific Hemoglobinopathies Market, by Test Type, Through 2026
  • Table 19 : Asia-Pacific Hemoglobinopathies Market, by Treatment, Through 2026
  • Table 20 : Asia-Pacific Hemoglobinopathies Market, by End-User, Through 2026
  • Table 21 : Asia-Pacific Hemoglobinopathies Market, by Country, Through 2026
  • Table 22 : South America Hemoglobinopathies Market, by Indication, Through 2026
  • Table 23 : South America Hemoglobinopathies Market, by Test Type, Through 2026
  • Table 24 : South America Hemoglobinopathies Market, by Treatment, Through 2026
  • Table 25 : South America Hemoglobinopathies Market, by End-User, Through 2026
  • Table 26 : South America Hemoglobinopathies Market, by Country, Through 2026
  • Table 27 : Middle East & Africa Hemoglobinopathies Market, by Indication, Through 2026
  • Table 28 : Middle East & Africa Hemoglobinopathies Market, by Test Type, Through 2026
  • Table 29 : Middle East & Africa Hemoglobinopathies Market, by Treatment, Through 2026
  • Table 30 : Middle East & Africa Hemoglobinopathies Market, by End-User, Through 2026
  • Table 31 : Middle East & Africa Hemoglobinopathies Market, by Country, Through 2026
  • Table 32 : Sangamo Therapeutics, Inc.: Financial Performance, Through 2020
  • Table 33 : Global Blood Therapeutics, Inc.: Financial Performance, Through 2020
  • Table 34 : Emmaus Life Sciences Inc.: Financial Performance, Through 2020
  • Table 35 : Pfizer, Inc.: Financial Performance, Through 2020
  • Table 36 : Novartis International AG: Financial Performance, Through 2020
  • Table 37 : Danaher Corporation: Financial Performance, Through 2020
  • Table 38 : Bio-Rad Laboratories Inc.: Financial Performance, Through 2020
  • Table 39 : PerkinElmer Inc.: Financial Performance, Through 2020
  • Table 40 : Acceleron Pharma, Inc.: Financial Performance, Through 2020
  • Table 41 : bluebird bio, Inc.: Financial Performance, Through 2020
  • Figure 1 : Global Hemoglobinopathies Market
  • Figure 2 : Global Hemoglobinopathies Market, by Value, 2019-2026
  • Figure 3 : Global Hemoglobinopathies Market, by Value, by Indication, 2019-2026
  • Figure 4 : Global Hemoglobinopathies Market, by Value, by Test Type, 2019-2026
  • Figure 5 : Global Hemoglobinopathies Market, by Value, by Treatment, 2019-2026
  • Figure 6 : Global Hemoglobinopathies Market, by Value, by End-User, 2019-2026
  • Figure 7 : Global Hemoglobinopathies Market, by Value, by Region, 2020
  • Figure 8 : Global Hemoglobinopathies Market, by Value, by Company, 2020
  • Figure 9 : Global Hemoglobinopathies Market, Product Map, 2020
  • Figure 10 : North America Hemoglobinopathies Market, by Value, 2019-2026
  • Figure 11 : North America Hemoglobinopathies Market, by Value, by Indication, 2019-2026
  • Figure 12 : North America Hemoglobinopathies Market, by Value, by Test Type, 2019-2026
  • Figure 13 : North America Hemoglobinopathies Market, by Value, by Treatment, 2019-2026
  • Figure 14 : North America Hemoglobinopathies Market, by Value, by End-User, 2019-2026
  • Figure 15 : North America Hemoglobinopathies Market, by Value, by Country, 2020
  • Figure 16 : Europe Hemoglobinopathies Market, by Value, 2019-2026
  • Figure 17 : Europe Hemoglobinopathies Market, by Value, by Indication, 2019-2026
  • Figure 18 : Europe Hemoglobinopathies Market, by Value, by Test Type, 2019-2026
  • Figure 19 : Europe Hemoglobinopathies Market, by Value, by Treatment, 2019-2026
  • Figure 20 : Europe Hemoglobinopathies Market, by Value, by End-User, 2019-2026
  • Figure 21 : Europe Hemoglobinopathies Market, by Value, by Country, 2020
  • Figure 22 : Asia-Pacific Hemoglobinopathies Market, by Value, 2019-2026
  • Figure 23 : Asia-Pacific Hemoglobinopathies Market, by Value, by Indication, 2019-2026
  • Figure 24 : Asia-Pacific Hemoglobinopathies Market, by Value, by Test Type, 2019-2026
  • Figure 25 : Asia-Pacific Hemoglobinopathies Market, by Value, by Treatment, 2019-2026
  • Figure 26 : Asia-Pacific Hemoglobinopathies Market, by Value, by End-User, 2019-2026
  • Figure 27 : Asia-Pacific Hemoglobinopathies Market, by Value, by Country, 2020
  • Figure 28 : South America Hemoglobinopathies Market, by Value, 2019-2026
  • Figure 29 : South America Hemoglobinopathies Market, by Value, by Indication, 2019-2026
  • Figure 30 : South America Hemoglobinopathies Market, by Value, by Test Type, 2019-2026
  • Figure 31 : South America Hemoglobinopathies Market, by Value, by Treatment, 2019-2026
  • Figure 32 : South America Hemoglobinopathies Market, by Value, by End-User, 2019-2026
  • Figure 33 : South America Hemoglobinopathies Market, by Value, by Country, 2020
  • Figure 34 : Middle East & Africa Hemoglobinopathies Market, by Value, 2019-2026
  • Figure 35 : Middle East & Africa Hemoglobinopathies Market, by Value, by Indication, 2019-2026
  • Figure 36 : Middle East & Africa Hemoglobinopathies Market, by Value, by Test Type, 2019-2026
  • Figure 37 : Middle East & Africa Hemoglobinopathies Market, by Value, by Treatment, 2019-2026
  • Figure 38 : Middle East & Africa Hemoglobinopathies Market, by Value, by End-User, 2019-2026
  • Figure 39 : Middle East & Africa Hemoglobinopathies Market, by Value, by Country, 2020
  • Figure 40 : Sangamo Therapeutics, Inc.: Revenue Share, 2020
  • Figure 41 : Global Blood Therapeutics, Inc.: Revenue Share, 2020
  • Figure 42 : Emmaus Life Sciences Inc.: Revenue Share, 2020
  • Figure 43 : Pfizer, Inc.: Revenue Share, 2020
  • Figure 44 : Novartis International AG: Revenue Share, 2020
  • Figure 45 : Danaher Corporation: Revenue Share, 2020
  • Figure 46 : Bio-Rad Laboratories Inc.: Revenue Share, 2020
  • Figure 47 : PerkinElmer Inc.: Revenue Share, 2020
  • Figure 48 : Acceleron Pharma, Inc.: Revenue Share, 2020
  • Figure 49 : bluebird bio, Inc.: Revenue Share, 2020

Market Research Studies is a North Carolina based, premier market research company. MRS brings over 50 years of market research publishing experience. Our reports cover a variety of industries such as Healthcare, Chemicals, Materials & Manufacturing, Research & Diagnostics, Environment & Sustainability, among others. Each year MRS releases hundreds of reports covering various topics. These reports are prepared by our in-house of team of Industry expert analysts. We strive to provide in-depth market analysis with accurate data to help our customers make informed decisions.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report